Thus, the effects of XPO1i may not be impacted by Bruton’s tyrosine kinase (BTK) inhibitors, indicating that this combination forms a rational anti-cancer strategy given the evidence of overlapping impact on key tumorigenic pathways like p53, mTOR and NF-κB. The gene discussed is TP53; the disease is cancer.